# Nucala (mepolizumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mepolizumab

> The FDA approved Nucala (mepolizumab), sponsored by GSK plc (GSK), on June 6, 2019.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Nucala (mepolizumab) |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [Asthma](https://sec-api.dev/indications/asthma), [Eosinophilic Granulomatosis With Polyangiitis](https://sec-api.dev/indications/eosinophilic-granulomatosis-with-polyangiitis), [Hypereosinophilic Syndrome](https://sec-api.dev/indications/hypereosinophilic-syndrome) |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### June 6, 2019: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761122 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20190606, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE; product NUCALA (MEPOLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761122%22

### September 25, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125526 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20200925, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE LLC; product NUCALA (MEPOLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125526%22

### July 29, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125526 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20210729, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE LLC; product NUCALA (MEPOLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125526%22
- openFDA Drugs@FDA: "BLA761122 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20210729, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE; product NUCALA (MEPOLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761122%22

### May 22, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125526 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20250522, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE LLC; product NUCALA (MEPOLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125526%22

### September 14, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04718389 (A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-14 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-05-18." https://clinicaltrials.gov/study/NCT04718389

### October 28, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Hypereosinophilic Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04965636 (Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-28 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-05-04." https://clinicaltrials.gov/study/NCT04965636

### May 4, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Hypereosinophilic Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04965636 (Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-28 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-05-04." https://clinicaltrials.gov/study/NCT04965636?tab=results

### May 18, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04718389 (A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-14 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-05-18." https://clinicaltrials.gov/study/NCT04718389?tab=results

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Eosinophilic Granulomatosis With Polyangiitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05263934 (Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT05263934

### September 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Eosinophilic Granulomatosis With Polyangiitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05263934 (Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT05263934

## Same indication

- [Amlitelimab](https://sec-api.dev/pdufa/amlitelimab) (SNY)
- [Aro-rage](https://sec-api.dev/pdufa/aro-rage) (ARWR)
- [Atuliflapon](https://sec-api.dev/pdufa/atuliflapon) (AZN)
- [AZD4604](https://sec-api.dev/pdufa/azd4604) (AZN)
- [AZD8630](https://sec-api.dev/pdufa/azd8630) (AZN)
- [Bda mdi](https://sec-api.dev/pdufa/bda-mdi) (AZN)
- [Bda mdi hfo 160/180 μg](https://sec-api.dev/pdufa/bda-mdi-hfo-160) (AZN)
- [Fasenra (benralizumab)](https://sec-api.dev/pdufa/benralizumab) (AZN)
- [Bff mdi](https://sec-api.dev/pdufa/bff-mdi) (AZN)
- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Budesonide/albuterol metered dose inhaler, mdi](https://sec-api.dev/pdufa/budesonide-albuterol-metered-dose-inhaler-mdi) (AZN)
- [Depemokimab](https://sec-api.dev/pdufa/depemokimab) (GSK)
- [Ff/umec/vi](https://sec-api.dev/pdufa/ff-umec-vi) (GSK)
- [Fp/abs](https://sec-api.dev/pdufa/fp-abs) (TEVA)
- [Qbrexza (glycopyrronium tosylate)](https://sec-api.dev/pdufa/glycopyrronium) (DERM)
- [Gp mdi](https://sec-api.dev/pdufa/gp-mdi) (AZN)
- [Gsk3511294 (depemokimab)](https://sec-api.dev/pdufa/gsk3511294-depemokimab) (GSK)
- [GSK5784283](https://sec-api.dev/pdufa/gsk5784283) (GSK)
- [HFA-152A](https://sec-api.dev/pdufa/hfa-152a) (GSK)
- [Intervention: as mdi](https://sec-api.dev/pdufa/intervention-as-mdi) (AZN)
- [JNJ-95597528](https://sec-api.dev/pdufa/jnj-95597528) (JNJ)
- [Londamocitinib](https://sec-api.dev/pdufa/londamocitinib) (AZN)
- [Lunsekimig](https://sec-api.dev/pdufa/lunsekimig) (SNY)
- [Pf-07275315 dose 1](https://sec-api.dev/pdufa/pf-07275315) (PFE)
- [QMF149](https://sec-api.dev/pdufa/qmf149) (NVS)
- [QVM149](https://sec-api.dev/pdufa/qvm149) (NVS)
- [Rocatinlimab](https://sec-api.dev/pdufa/rocatinlimab) (AMGN)
- [Salbutamol hfa-134a](https://sec-api.dev/pdufa/salbutamol-hfa-134a) (GSK)
- [TEV-56248](https://sec-api.dev/pdufa/tev-56248) (TEVA)
- [TEZSPIRE® (tezepelumab)](https://sec-api.dev/pdufa/tezepelumab) (AZN)
- [Tilrekimig](https://sec-api.dev/pdufa/tilrekimig) (PFE)
- [Tozorakimab](https://sec-api.dev/pdufa/tozorakimab) (AZN)
- [WIN378](https://sec-api.dev/pdufa/win378) (WWB)

Calendar months: [September 2026](https://sec-api.dev/fda-calendar/2026-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mepolizumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Nucala (mepolizumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mepolizumab

```bibtex
@misc{secapidev_pdufa_mepolizumab_20261116,
  title        = {Nucala (mepolizumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mepolizumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mepolizumab_20261116","title":"Nucala (mepolizumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mepolizumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
